Navigation Links
Masimo Reports Third Quarter 2010 Financial Results

IRVINE, Calif., Nov. 2, 2010 /PRNewswire-FirstCall/ --

Q3 2010 Highlights (compared to Q3 2009):

  • Total revenue rose 15.5% to $101.0 million
  • Product revenue rose 18.2% to $88.8 million
  • Masimo SET and Masimo rainbow SET unit shipments rose 43.1% to 37,500
  • Masimo rainbow revenue rose 98.7% to $11.9 million
  • GAAP EPS rose 22.7% to $0.27.  Excluding $0.01 in one-time expenses, adjusted EPS rose 27.3% to $0.28

  • Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter of 2010.

    Masimo’s total revenue for the third quarter rose 15.5% to $101.0 million, compared to $87.4 million for the third quarter of 2009.  Masimo’s third quarter product revenue rose 18.2% to $88.8 million, compared to $75.1 million for the third quarter of 2009.  Revenue from Masimo rainbow products rose 98.7% to $11.9 million in the third quarter, compared to $6.0 million for the third quarter of 2009.  

    Net income for the third quarter was $16.4 million, or $0.27 per diluted share, including $0.01 per diluted share in one-time marketing-related expenses that Masimo had previously planned and announced after receiving $30.1 million in proceeds in the first quarter of 2010 from an antitrust lawsuit against Covidien.  Excluding these one-time expenses, adjusted net income for the third quarter was $16.9 million, or $0.28 per diluted share, compared to net income of $13.1 million, or $0.22 per diluted share, in the third quarter of 2009.  

    During the third quarter, the company shipped approximately 37,500 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 43.1% compared to approximately 26,200 in the same period last year.  Masimo estimates its worldwide installed base as of October 2, 2010 to be 821,000 units, up 17.8% from 697,000 units as of October 3, 2009.Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “Masimo continues to pursue its mission to improve patient outcomes and reduce healthcare costs by taking noninvasive monitoring to new sites and applications.  Our third-quarter results demonstrate the strength of our technology and mission.”  

    As of October 2, 2010, cash, cash equivalents and short-term investments totaled $125.4 million, compared to $189.0 million as of January 2, 2010.  The decline was due primarily to the March 31, 2010 dividend payment of $117.5 million, partially offset by the net proceeds from the antitrust lawsuit and operating cash flow in the first nine months of 2010.Conference Call Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results.  The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 679-9937 for international callers. The reservation code for both dial-in numbers is 17706796. After the live webcast, the call will be available on Masimo's website through December 2, 2010. In addition, a telephonic replay of the call will be available through November 16, 2010. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706) 645-9291 for international callers. Please use reservation code 17706796.

    About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at

    Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our financial condition, results of operations and business generally.  These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce the anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact: Sheree Aronson

    Media Contact: Dana BanksVice President, Investor Relations, Masimo Corporation

    Manager, Public Relations, Masimo Corporation (949) 297-7043

    (949) 297-7348

    dbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5, Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine  are trademarks or registered trademarks of Masimo Corporation.

    MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) October 2,January 2,20102010ASSETSCurrent assetsCash and cash equivalents

    $ 125,407$ 132,054Short-term investments

    —56,989Accounts receivable, net of allowance for doubtful accounts

    49,33038,897Royalties receivable


    43,40131,559Prepaid expenses

    4,9665,447Deferred tax assets

    11,58611,585Other current assets

    1,7291,357Total current assets

    247,919289,388Deferred cost of goods sold

    35,33428,163Property and equipment, net

    13,82211,682Deferred tax assets

    11,38011,500Intangible assets, net

    10,2949,829Other assets

    8,1175,783Total assets

    $ 326,866$ 356,345LIABILITIES AND EQUITYCurrent liabilitiesAccounts payable

    $   23,892$   16,716Accrued compensation

    19,47817,793Accrued liabilities

    10,8149,754Income taxes payable

    1,021477Deferred revenue

    14,62414,641Current portion of capital lease obligations

    5460Total current liabilities

    69,88359,441Deferred revenue

    1,979270Capital lease obligations, less current portion

    134171Other liabilities

    7,4906,775Total liabilities

    79,48666,657EquityMasimo Corporation stockholders’ equity:Common stock

    5958Treasury stock

    (1,209)(1,209)Additional paid-in capital

    211,882195,690Accumulated other comprehensive income

    77563Retained earnings

    34,02294,112Total Masimo Corporation stockholders’ equity

    245,529288,714Noncontrolling interest

    1,851974Total equity

    247,380289,688Total liabilities and equity

    $ 326,866$ 356,345MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except per share amounts) Three Months EndedNine Months EndedOctober 2,October 3,October 2,October 3,2010200920102009Revenue:Product

    262,647$ 219,690Royalty

    12,16512,29537,18636,812Total revenue

    100,98887,441299,833256,502Cost of goods sold

    29,37625,19888,37973,517Gross profit

    71,61262,243211,454182,985Operating expenses:Research and development

    9,2277,74227,68822,761Selling, general and administrative

    39,54733,476129,86299,122Antitrust litigation expense (proceeds)

    —185(30,728)228Total operating expenses

    48,77441,403126,822122,111Operating income

    22,83820,84084,63260,874Non-operating income

    1,2322951,194376Income before provision for income taxes

    24,07021,13585,82661,250Provision for income taxes

    7,3767,81429,05221,414Net income including noncontrolling interests

    16,69413,32156,77439,836Net (income) loss attributable to the noncontrolling interests

    (275)(266)642(668)Net income attributable to Masimo Corporation

    $   16,419$
    57,416$   39,168Net income per share attributable to Masimo Corporation



    .65Weighted average shares used in per share calculations:Basic


    60,57260,15760,52760,127Cash dividend declared per share

    8212;The following table presents details of the share-based compensation expense that is included in each functional line item in the condensed consolidated statements of income above (in thousands): Three Months EndedNine Months EndedOctober 2,October 3,October 2,October 3,2010200920102009Cost of goods sold

    273Research and development

    ,878Selling, general and administrative

    $  1,777$
    5,752MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands) Nine Months EndedOctober 2,October 3,20102009Cash flows from operating activities:Net income including noncontrolling interests

    $   56,774$  39,836Adjustments to reconcile net income including noncontrolling interests

    to net cash provided by operating activities: Depreciation and amortization

    4,7554,512Share-based compensation

    8,8877,903Loss on disposal of property and equipment

    —3Provision for doubtful accounts

    129682Provision for obsolete inventory

    448346Provision for warranty costs

    1,7901,582Provision for deferred income taxes

    133—Income tax benefit from exercise of stock options granted prior to

    January 1, 2006

    2,0721,403Excess tax benefit from share-based payment arrangements

    (494)(185)Changes in operating assets and liabilities:Increase in accounts receivable

    (10,561)(9,377)Increase in royalties receivable

    —(59)Increase in inventories

    (12,290)(4,233)(Increase) decrease in deferred cost of goods sold

    (7,201)891(Increase) decrease in prepaid expenses

    522(2,407)Increase in other assets

    (2,717)(1,165)Increase (decrease) in accounts payable

    7,189(2,124)Increase in accrued compensation

    1,6501,191Decrease in accrued liabilities

    (734)(48)Increase (decrease) in income taxes payable

    1,036(9,781)Increase (decrease) in deferred revenue

    1,691(99)Increase in other liabilities

    677833Net cash provided by operating activities

    53,75629,704Cash flows from investing activities:Purchase of short-term investments

    (75,986)—Proceeds from sale and maturities of short-term investments

    132,975—Purchases of property and equipment

    (5,942)(2,889)Increase in intangible assets

    (1,381)(1,100)(Increase) decrease in restricted cash

    42(15)Net cash provided by (used in) investing activities

    49,708(4,004)Cash flows from financing activities:Repayments on long-term debt

    (43)(268)Proceeds from issuance of common stock

    6,2771,834Excess tax benefit from share-based payment arrangements

    494185Dividends paid

    (117,506)—Net cash provided by (used in) financing activities

    (110,778)1,751Effect of foreign currency exchange rates on cash

    667325Net increase (decrease) in cash and cash equivalents

    (6,647)27,776Cash and cash equivalents at beginning of period

    132,054146,910Cash and cash equivalents at end of period

    $ 125,407$174,686

    SOURCE Masimo Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
    2. Masimo to Report Third Quarter 2010 Financial Results After Market Close on November 2, 2010
    3. New Multi-Center Study Finds Clinical Practice Change with Masimo SET Pulse Oximetry Reduces Severe Eye Damage More Than 50% in Premature Newborns
    4. Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan
    5. Palmetto Health Richland Hospital Becomes First in South Carolina to Noninvasively, Wirelessly Monitor Patients Using State-of-the-Art Masimo Patient SafetyNet™ System
    6. Masimo to Present at Stifel Nicolaus 2010 Healthcare Conference
    7. Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology
    8. Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
    9. Frankfurt am Main Emergency Medical Services Makes Masimo Rad-57 Pulse CO-Oximeters Mandatory for All Vehicles
    10. Premier Members to Benefit from Full Line of Market-Leading Masimo rainbow Pulse CO-Oximetry Solutions with New Agreement
    11. St.Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET(R) Pulse Oximetry Technology
    Post Your Comments:
    (Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... that its MyDario product is expected to appear on The Dr. Oz ... Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked ... The segment features ...
    (Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
    (Date:9/13/2017)...   OrthoAtlanta has been named the official orthopedic ... (AFHC) for the 2018 College Football Playoff (CFP) National Championship ... Stadium in Atlanta, Georgia . OrthoAtlanta is ... campaign, participating in many activities leading up to, and including ... ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
    (Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
    (Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
    Breaking Medicine News(10 mins):